menu
    • menu

    Company profile for Ambrosia Biosciences

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ambrosia Biosciences is a biotechnology company focused on developing orally delivered, small molecule therapies for obesity and metabolic disorders. Leveraging advanced structural biology, AI-driven molecular design, and integrated chemistry and biology platforms, the company accelerates drug discovery from hit identification to IND. With deep expertise in GPCR-targeted therapeutics and a strong scientific track record, Ambro...
    Ambrosia Biosciences is a biotechnology company focused on developing orally delivered, small molecule therapies for obesity and metabolic disorders. Leveraging advanced structural biology, AI-driven molecular design, and integrated chemistry and biology platforms, the company accelerates drug discovery from hit identification to IND. With deep expertise in GPCR-targeted therapeutics and a strong scientific track record, Ambrosia aims to deliver safe, effective, and scalable treatments for cardiometabolic diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ambrosia BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1885 33rd St, Boulder, CO 80301
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ambrosiabiosciences.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ambrosia Bio Presents Preclinical Data on AMB-702 GLP-1 RA
    Ambrosia Bio Presents Preclinical Data on AMB-702 GLP-1 RA

    07 Jun 2026

    // BIOSPACE

    https://www.biospace.com/press-releases/ambrosia-biosciences-announces-preclinical-data-supporting-differentiated-profile-of-amb-702-its-novel-small-molecule-glp-1-receptor-agonist-development-candidate

    BIOSPACE
    07 Jun 2026
    Share Share
    Ambrosia Biosciences Presents Late-Breaking Poster at 86th ADA
    Ambrosia Biosciences Presents Late-Breaking Poster at 86th ADA

    21 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7197378

    FIRSTWORD PHARMA
    21 Apr 2026
    Share Share
    Ambrosia Bio Closes $100M Series B for Cardiometabolic Pipeline
    Ambrosia Bio Closes $100M Series B for Cardiometabolic Pipeline

    31 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ambrosia-biosciences-announces-100-million-oversubscribed-series-b-financing-to-advance-novel-small-molecule-cardiometabolic-pipeline-302729104.html

    PR NEWSWIRE
    31 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search